To strengthen its position in sterile filling, Siegfried Group has agreed to acquire Hameln Pharma, consisting of Hameln Pharmaceuticals GmbH and Hameln RDS GmbH, for approximately CHF 60 million ($62 million). Hameln Pharma focuses on the development and production of sterile liquid pharmaceutical products and expects 2014 sales of approximately CHF 85 million ($88 million). The acquired companies employ a workforce of approximately 500. Under terms of the acquisition agreement, Siegfried will take over the entire staff.

Hameln Pharma produces sterile liquid drugs filled in ampuls or vials for international pharmaceutical companies. The focus of its activities is on the production of demanding compounds, such as anesthetics. To supplement its core business of contract manufacturing, Hameln Pharma offers a portfolio of accompanying services ranging from product and method development to dossier compilation and registration services.

Hameln Pharma is part of the Hameln Group. The Hameln Group with its remaining subsidiaries will focus on their own brand of injectable pharmaceutical finished products. The research and development site in Slovakia will also remain in the possession of the Hameln Group.

With this acquisition, Siegfried has implemented its strategy regarding both forward and backward integration. In 2012, Siegfried acquired Alliance Medical Products, Inc. in Irvine, California, active in a comparable market segment as Hameln Pharma. In October 2014, the company gained internal approval for a new chemical production plant for active pharmaceutical ingredients in Nantong, China. This Siegfried site has a chemical-pharmaceutical capacity of more than 300 cubic meters. At its headquarters in Zofingen, Switzerland, Siegfried is currently building a chemical production plant with a capacity of 100 cubic meters, which from mid-2015, will replace older and less efficient facilities.

Source: Siegfried Group